WO2003105770A3 - Carbocyclic nucleoside analogs as rna-antivirals - Google Patents
Carbocyclic nucleoside analogs as rna-antivirals Download PDFInfo
- Publication number
- WO2003105770A3 WO2003105770A3 PCT/US2003/018841 US0318841W WO03105770A3 WO 2003105770 A3 WO2003105770 A3 WO 2003105770A3 US 0318841 W US0318841 W US 0318841W WO 03105770 A3 WO03105770 A3 WO 03105770A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rna
- inhibitors
- dependent rna
- carbocyclic nucleoside
- infection
- Prior art date
Links
- -1 Carbocyclic nucleoside Chemical class 0.000 title abstract 4
- 239000002777 nucleoside Substances 0.000 title abstract 4
- 239000003443 antiviral agent Substances 0.000 title 1
- 229940121357 antivirals Drugs 0.000 title 1
- 230000001419 dependent effect Effects 0.000 abstract 6
- 241000711549 Hepacivirus C Species 0.000 abstract 4
- 239000003112 inhibitor Substances 0.000 abstract 4
- 208000036142 Viral infection Diseases 0.000 abstract 3
- 230000009385 viral infection Effects 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000029812 viral genome replication Effects 0.000 abstract 2
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 108060004795 Methyltransferase Proteins 0.000 abstract 1
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002488842A CA2488842A1 (en) | 2002-06-17 | 2003-06-14 | Carbocyclic nucleoside analogs as rna-antivirals |
AU2003251524A AU2003251524A1 (en) | 2002-06-17 | 2003-06-14 | Carbocyclic nucleoside analogs as RNA-antivirals |
JP2004512678A JP2005533777A (en) | 2002-06-17 | 2003-06-14 | Carbocyclic nucleoside analogs as RNA antiviral agents |
EP03760371A EP1515971A2 (en) | 2002-06-17 | 2003-06-14 | Carbocyclic nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38916102P | 2002-06-17 | 2002-06-17 | |
US60/389,161 | 2002-06-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003105770A2 WO2003105770A2 (en) | 2003-12-24 |
WO2003105770A3 true WO2003105770A3 (en) | 2004-10-07 |
Family
ID=29736594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/018841 WO2003105770A2 (en) | 2002-06-17 | 2003-06-14 | Carbocyclic nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1515971A2 (en) |
JP (1) | JP2005533777A (en) |
AU (1) | AU2003251524A1 (en) |
CA (1) | CA2488842A1 (en) |
WO (1) | WO2003105770A2 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7429572B2 (en) | 2003-05-30 | 2008-09-30 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
US7456155B2 (en) | 2002-06-28 | 2008-11-25 | Idenix Pharmaceuticals, Inc. | 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
US7582618B2 (en) | 2002-06-28 | 2009-09-01 | Idenix Pharmaceuticals, Inc. | 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
US7598373B2 (en) | 2002-12-12 | 2009-10-06 | Idenix Pharmaceuticals, Inc. | Process for the production of 2-C-methyl-D-ribonolactone |
US7608597B2 (en) | 2000-05-23 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus |
US7645745B2 (en) | 2006-04-04 | 2010-01-12 | Roche Palo Alto Llc | Antiviral nucleosides |
US7786110B2 (en) | 2006-11-09 | 2010-08-31 | Roche Palo Alto Llc | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
US7858654B2 (en) | 2007-12-17 | 2010-12-28 | Roche Palo Alto Llc | Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
US7989637B2 (en) | 2007-12-17 | 2011-08-02 | Roche Palo Alto Llc | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
US8048905B2 (en) | 2007-12-17 | 2011-11-01 | Roche Palo Alto Llc | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
US8440673B2 (en) | 2007-12-17 | 2013-05-14 | Roche Palo Alto Llc | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
US8957046B2 (en) | 2007-03-30 | 2015-02-17 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
US9045520B2 (en) | 2008-12-23 | 2015-06-02 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
US9243025B2 (en) | 2011-03-31 | 2016-01-26 | Idenix Pharmaceuticals, Llc | Compounds and pharmaceutical compositions for the treatment of viral infections |
US9393256B2 (en) | 2011-09-16 | 2016-07-19 | Gilead Pharmasset Llc | Methods for treating HCV |
US9549941B2 (en) | 2011-11-29 | 2017-01-24 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030036189A (en) | 2000-05-26 | 2003-05-09 | 이데닉스(케이만)리미티드 | Methods and compositions for treating flaviviruses and pestiviruses |
TW200500374A (en) * | 2002-06-28 | 2005-01-01 | Idenlx Cayman Ltd | 2' and 3' -nucleoside produrgs for treating flavivridae infections |
AU2003256619A1 (en) | 2002-07-24 | 2004-02-09 | Isis Pharmaceuticals, Inc. | Pyrrolopyrimidine thionucleoside analogs as antivirals |
PT1576138T (en) | 2002-11-15 | 2017-05-03 | Idenix Pharmaceuticals Llc | 2'-methyl nucleosides in combination with interferon and flaviviridae mutation |
CN103304541A (en) | 2004-02-20 | 2013-09-18 | 贝林格尔.英格海姆国际有限公司 | Viral polymerase inhibitors |
CN101023094B (en) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives |
KR101177590B1 (en) | 2004-09-14 | 2012-08-27 | 파마셋 인코포레이티드 | Preparation of 2'-fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
KR20070073805A (en) * | 2004-09-24 | 2007-07-10 | 이데닉스 (케이만) 리미티드 | Methods and compositions for treating flaviviruses, pestiviruses and hepaciviruses |
US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
ES2758027T3 (en) | 2007-08-02 | 2020-05-04 | Millennium Pharm Inc | Intermediates for the synthesis of E1 activity activating enzyme inhibitors |
CA2724523A1 (en) | 2008-06-06 | 2010-01-07 | Scynexis, Inc. | Novel macrocyclic peptides |
TWI409265B (en) * | 2008-08-20 | 2013-09-21 | Merck Sharp & Dohme | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
SG172359A1 (en) | 2008-12-23 | 2011-07-28 | Pharmasset Inc | Nucleoside phosphoramidates |
NZ617066A (en) | 2008-12-23 | 2015-02-27 | Gilead Pharmasset Llc | Nucleoside analogs |
TWI576352B (en) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | Nucleoside phosphoramidates |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
EP2445889B1 (en) | 2009-06-22 | 2016-08-10 | F.Hoffmann-La Roche Ag | Novel benzoxazolone -substituted arylamides |
JP5540087B2 (en) | 2009-06-22 | 2014-07-02 | エフ.ホフマン−ラ ロシュ アーゲー | Novel indoles, indazoles and benzimidazole arylamides as P2X3 and / or P2X2 / 3 antagonists |
EP2445868B1 (en) | 2009-06-22 | 2013-12-18 | F.Hoffmann-La Roche Ag | Biphenyl amides useful as p2x3 and/or p2x2/3 receptors modulators |
KR20120104239A (en) | 2009-11-14 | 2012-09-20 | 에프. 호프만-라 로슈 아게 | Biomarkers for predicting rapid response to hcv treatment |
AU2010326781A1 (en) | 2009-12-02 | 2012-04-19 | F. Hoffmann-La Roche Ag | Biomarkers for predicting sustained response to HCV treatment |
PL2552930T3 (en) | 2010-03-31 | 2016-02-29 | Gilead Pharmasset Llc | Crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1-(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate |
TW201136945A (en) | 2010-03-31 | 2011-11-01 | Pharmasset Inc | Purine nucleoside phosphoramidate |
EP2552203B1 (en) | 2010-04-01 | 2017-03-22 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
EP2755983B1 (en) | 2011-09-12 | 2017-03-15 | Idenix Pharmaceuticals LLC. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
US8507460B2 (en) | 2011-10-14 | 2013-08-13 | Idenix Pharmaceuticals, Inc. | Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
US9109001B2 (en) | 2012-05-22 | 2015-08-18 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphoramidate prodrugs for HCV infection |
WO2013177219A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | D-amino acid compounds for liver disease |
US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
KR20150014457A (en) | 2012-05-25 | 2015-02-06 | 얀센 알 앤드 디 아일랜드 | Uracyl spirooxetane nucleosides |
US9192621B2 (en) | 2012-09-27 | 2015-11-24 | Idenix Pharmaceuticals Llc | Esters and malonates of SATE prodrugs |
WO2014058801A1 (en) | 2012-10-08 | 2014-04-17 | Idenix Pharmaceuticals, Inc. | 2'-chloro nucleoside analogs for hcv infection |
EP2909222B1 (en) | 2012-10-22 | 2021-05-26 | Idenix Pharmaceuticals LLC | 2',4'-bridged nucleosides for hcv infection |
EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
SG10201706949VA (en) | 2013-01-31 | 2017-09-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
US20140271547A1 (en) | 2013-03-13 | 2014-09-18 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
RU2534613C2 (en) | 2013-03-22 | 2014-11-27 | Александр Васильевич Иващенко | Alkyl2-{[(2r,3s,5r)-5-(4-amino-2-oxo-2h-pyrimidine-1-yl)- -hydroxy- tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-proptonates, nucleoside inhibitors of rna-polymerase hcv ns5b, methods for producing and using them |
EP2981542B1 (en) | 2013-04-01 | 2021-09-15 | Idenix Pharmaceuticals LLC | 2',4'-fluoro nucleosides for the treatment of hcv |
CN104151360B (en) * | 2013-05-14 | 2019-02-22 | 北京美倍他药物研究有限公司 | Phosphoric acid/phosphonate derivative and its medical usage |
EP3004130B1 (en) | 2013-06-05 | 2019-08-07 | Idenix Pharmaceuticals LLC. | 1',4'-thio nucleosides for the treatment of hcv |
US20150037282A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
SI3038601T1 (en) | 2013-08-27 | 2020-07-31 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
CN103524423B (en) | 2013-09-18 | 2015-11-04 | 苏州乔纳森新材料科技有限公司 | The preparation method of 4,6-dichloro-pyrimidine-5-acetaldehyde |
CN103554035B (en) * | 2013-10-29 | 2015-07-15 | 苏州乔纳森新材料科技有限公司 | Preparation method of 4,6-dihalogenated pyridine-5-aldehyde |
WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
WO2016134056A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
WO2016134054A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
WO2016134057A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
WO2016134051A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
CA2997170A1 (en) | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral tetrahydrofurane derivatives |
CN109956975B (en) * | 2017-12-22 | 2020-11-06 | 浙江柏拉阿图医药科技有限公司 | Liver delivery entecavir prodrug nucleoside cyclic phosphate ester compound and application thereof |
CN109761984B (en) * | 2019-02-27 | 2020-07-07 | 河南师范大学 | Method for the synthesis of chiral five-membered carbocyclic purine nucleosides by asymmetric hydrogen transfer |
CN112274516B (en) * | 2020-10-26 | 2022-08-05 | 中山大学附属第三医院 | Novel iodine-containing antiviral drug |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5409906A (en) * | 1987-04-16 | 1995-04-25 | Medivir Ab | α nucleoside compounds and a method for treating HBV using said compounds |
US5473063A (en) * | 1990-10-02 | 1995-12-05 | Medivir Ab | Synthesis of furanosyl compounds useful as intermediates in preparation of nucleoside analogues |
US5723466A (en) * | 1991-12-06 | 1998-03-03 | Hoechst Marion Roussel, Inc. | Trans cyclopentanyl purine analogs useful as immunosuppressants |
-
2003
- 2003-06-14 AU AU2003251524A patent/AU2003251524A1/en not_active Abandoned
- 2003-06-14 EP EP03760371A patent/EP1515971A2/en not_active Withdrawn
- 2003-06-14 WO PCT/US2003/018841 patent/WO2003105770A2/en active Application Filing
- 2003-06-14 CA CA002488842A patent/CA2488842A1/en not_active Abandoned
- 2003-06-14 JP JP2004512678A patent/JP2005533777A/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5409906A (en) * | 1987-04-16 | 1995-04-25 | Medivir Ab | α nucleoside compounds and a method for treating HBV using said compounds |
US5473063A (en) * | 1990-10-02 | 1995-12-05 | Medivir Ab | Synthesis of furanosyl compounds useful as intermediates in preparation of nucleoside analogues |
US5723466A (en) * | 1991-12-06 | 1998-03-03 | Hoechst Marion Roussel, Inc. | Trans cyclopentanyl purine analogs useful as immunosuppressants |
Non-Patent Citations (2)
Title |
---|
CAAMANO ET AL: "Synthesis and evaluation of antiviral activity of higher homologues of xylo-carbocyclic nucleosides", NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, vol. 20, no. 4-7, 2001, pages 1137 - 1139, XP002978490 * |
ROSENQUIST ET AL: "Synthesis of carbocyclic 2',3'-dideoxy-2'-C-hydroxymethyl nucleosides as potential inhibitors of HIV", J. ORG. CHEM., vol. 59, 1994, pages 1779 - 1782, XP002978470 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7608597B2 (en) | 2000-05-23 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus |
US7456155B2 (en) | 2002-06-28 | 2008-11-25 | Idenix Pharmaceuticals, Inc. | 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
US7582618B2 (en) | 2002-06-28 | 2009-09-01 | Idenix Pharmaceuticals, Inc. | 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
US7598373B2 (en) | 2002-12-12 | 2009-10-06 | Idenix Pharmaceuticals, Inc. | Process for the production of 2-C-methyl-D-ribonolactone |
US7429572B2 (en) | 2003-05-30 | 2008-09-30 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
US7645745B2 (en) | 2006-04-04 | 2010-01-12 | Roche Palo Alto Llc | Antiviral nucleosides |
US7786110B2 (en) | 2006-11-09 | 2010-08-31 | Roche Palo Alto Llc | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
US8957046B2 (en) | 2007-03-30 | 2015-02-17 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
US9585906B2 (en) | 2007-03-30 | 2017-03-07 | Gilead Pharmasset Llc | Nucleoside phosphoramidate prodrugs |
US7989637B2 (en) | 2007-12-17 | 2011-08-02 | Roche Palo Alto Llc | Triazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
US8048905B2 (en) | 2007-12-17 | 2011-11-01 | Roche Palo Alto Llc | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
US8440673B2 (en) | 2007-12-17 | 2013-05-14 | Roche Palo Alto Llc | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
US7858654B2 (en) | 2007-12-17 | 2010-12-28 | Roche Palo Alto Llc | Imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
US9045520B2 (en) | 2008-12-23 | 2015-06-02 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
US9394331B2 (en) | 2010-11-30 | 2016-07-19 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
US9243025B2 (en) | 2011-03-31 | 2016-01-26 | Idenix Pharmaceuticals, Llc | Compounds and pharmaceutical compositions for the treatment of viral infections |
US9393256B2 (en) | 2011-09-16 | 2016-07-19 | Gilead Pharmasset Llc | Methods for treating HCV |
US9549941B2 (en) | 2011-11-29 | 2017-01-24 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
Also Published As
Publication number | Publication date |
---|---|
JP2005533777A (en) | 2005-11-10 |
EP1515971A2 (en) | 2005-03-23 |
AU2003251524A1 (en) | 2003-12-31 |
CA2488842A1 (en) | 2003-12-24 |
WO2003105770A2 (en) | 2003-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003105770A3 (en) | Carbocyclic nucleoside analogs as rna-antivirals | |
JO2318B1 (en) | Nucleoside derivatives as inhibitors of rna-dependet rna viral polymerase | |
WO2004007512A3 (en) | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | |
WO2004000858A3 (en) | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | |
WO2004003138A3 (en) | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | |
WO2005123087A3 (en) | C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase | |
WO2004009020A3 (en) | Pyrrolopyrimidine thionucleoside analogs as antivirals | |
WO2006012078A3 (en) | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection | |
WO2007021610A3 (en) | Ribonucleoside cyclic acetal derivatives for the treatment of rna-dependent rna viral infection | |
WO2007095269A3 (en) | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection | |
WO2006065335A3 (en) | Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection | |
TW200612898A (en) | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same | |
WO2008085508A3 (en) | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection | |
DE60319820D1 (en) | PYRAZOLOE1,5-ATPYRIMIDIN COMPOUNDS AS ANTIVIRAL AGENTS | |
BRPI0415883A (en) | nucleoside compounds and compositions for the treatment of viral infections | |
WO2007025043A3 (en) | Seven-membered ring nucleosides | |
ECSP034699A (en) | NUCLEOSID COMPOUNDS AS VIRAL-DEPENDING RNA RNA POLYMERASE INHIBITORS | |
TW200745107A (en) | Anti-viral compounds | |
TH66557A (en) | Nucleoside derivatives are RNA inhibitors of viral polymers that depend on RNA. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003251524 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2488842 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003760371 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004512678 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003760371 Country of ref document: EP |